Additional file 2: of l-carnitine in critically ill patients—a case series study

Figure S2. Distribution of carnitine concentrations on ICU admission. (a) The distribution of t-Carnitine on ICU admission is shown in the histogram. The mean t-Carnitine was 94.9 ± 79.6 nmol/mL, and the median t-Carnitine was 64.2 (50.5–102.3) nmol/mL. (b) The distribution of f-Carnitine on ICU admission is shown in the histogram. The mean f-Carnitine was 68.6 ± 51.2 nmol/mL, and the median f-Carnitine was 50.5 (36.8–80.3) nmol/mL. (ZIP 160 kb

Additional file 5: of l-carnitine in critically ill patients—a case series study

Table S1. Clinical outcomes according to f-carnitine levels at ICU admissiona. (DOCX 21 kb

Additional file 1: of l-carnitine in critically ill patients—a case series study

Figure S1. Flowchart of study enrollment. (TIFF 117 kb

Additional file 4: of l-carnitine in critically ill patients—a case series study

Figure S4. Correlation of BMI and SOFA score with the change in f-Carnitine from day 0 to day 14. (a) Each plot depicts a relationship between the BMI on the x-axis, and the change of f-Carnitine from day 0 to day 14 (Δ f-Carnitine) on the y-axis. There was a significant negative correlation between the BMI and the Δf-Carnitine (r = − 0.47, p = 0.01), which suggests an association between lower BMI and larger decrease of f-Carnitine. (b) Each plot depicts a relationship between the SOFA score at the time of ICU admission on the x-axis, and the change of f-Carnitine from day 0 to day 14 (Δ f-Carnitine) on the y-axis. There was a significant correlation between the SOFA score on ICU admission and the Δf-Carnitine (r = 0.46, p = 0.01), which suggests an association between high SOFA score and larger decrease of f-Carnitine. (ZIP 188 kb

Additional file 3: of l-carnitine in critically ill patients—a case series study

Figure S3. Comparison of f-Carnitine transition among the patients with f-Carnitine increased and decreased. The transition of f-Carnitine area for 14 days plotted at each sampling point. The round and square signs within the figure indicate the medians for f-Carnitine, and the error bars indicate 25th and 75th percentile range. The dotted lines indicate the upper and lower reference values for f-Carnitine. The patients whose data are lacking at day 7 or day 14 were excluded from this analysis. (TIFF 123 kb

Additional file 1 of Chest CT findings in severe acute respiratory distress syndrome requiring V-V ECMO: J-CARVE registry

Additional file 1: SMethods. Figure S1. Representative images of each of the characteristic pulmonary opacities on chest computed tomography scans. Figure S2. Distribution of registered patients by years. Figure S3. Cumulative proportion of the duration (h) between chest computed tomography examinations and initiation of veno-venous extracorporeal membrane oxygenation support. Figure S4. Characteristics of the chest computed tomography findings according to the mechanical ventilation–extracorporeal membrane oxygenation support duration and the underlying etiology of the acute respiratory distress syndrome. Figure S5. Survival curve of the chest computed tomography findings related to changes outside of the pulmonary opacity (excluding subcutaneous emphysema). Figure S6. Survival curve of participants with and without traction bronchiectasis separately according to the underlying etiology of acute respiratory distress syndrome. Table S1. Concordance rates between two evaluators. Table S2. Basic information of the participating hospitals. Table S3. Characteristics of chest computed tomography findings. Table S4. Results of multivariate Cox regression analysis of the relationship between V-V ECMO support initiation and 90-day in-hospital mortality. Table S5. Results of multivariate logistic regression analysis for successful ECMO liberation